Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

<br><strong>Background </strong>Pain is a core domain of psoriatic arthritis (PsA). This post hoc analysis evaluated time to pain improvement and the impact of baseline pain severity on pain response in patients with PsA receiving tofacitinib. <br><strong> Methods </...

Bibliografiset tiedot
Päätekijät:	de Vlam, K, Ogdie, A, Bushmakin, AG, Cappelleri, JC, Fleischmann, R, Taylor, PC, Azevedo, V, Fallon, L, Woolcott, J, Mease, PJ
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	BMJ Publishing Group 2021

Samankaltaisia teoksia

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
Tekijä: de Vlam, K, et al.
Julkaistu: (2018)

Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis
Tekijä: Ogdie, A, et al.
Julkaistu: (2018)

Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis
Tekijä: de Vlam, K, et al.
Julkaistu: (2022)

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation
Tekijä: Taylor, P, et al.
Julkaistu: (2019)

Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease
Tekijä: Taylor, PC, et al.
Julkaistu: (2020)

The effect of tofacitinib on residual pain in patients with psoriatic arthritis
Tekijä: Dougados, M, et al.
Julkaistu: (2020)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
Tekijä: Iain B McInnes, et al.
Julkaistu: (2020-02-01)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
Tekijä: Dougados, M, et al.
Julkaistu: (2022)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
Tekijä: Maxime Dougados, et al.
Julkaistu: (2022-11-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
Tekijä: Gladman, DD, et al.
Julkaistu: (2022)

Itch as major mediator of effect of tofacitinib on health-related quality of life in psoriatic arthritis: a mediation analysis
Tekijä: Taylor, PC, et al.
Julkaistu: (2021)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
Tekijä: Coates, L, et al.
Julkaistu: (2021)

Pain and inflammation as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis
Tekijä: Kristensen, LE, et al.
Julkaistu: (2023)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Tekijä: Philip J. Mease, et al.
Julkaistu: (2024-01-01)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
Tekijä: Taylor, P, et al.
Julkaistu: (2022)

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis
Tekijä: Daniela Graham, et al.
Julkaistu: (2021-04-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
Tekijä: Dafna D. Gladman, et al.
Julkaistu: (2022-02-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
Tekijä: Laura C. Coates, et al.
Julkaistu: (2021-03-01)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
Tekijä: Peter C. Taylor, et al.
Julkaistu: (2022-07-01)

Measuring outcomes in psoriatic arthritis
Tekijä: Ogdie, A, et al.
Julkaistu: (2020)

Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
Tekijä: Alexis Ogdie, et al.
Julkaistu: (2024-09-01)

Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation Analysis
Tekijä: Lars Erik Kristensen, et al.
Julkaistu: (2023-06-01)

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
Tekijä: Nash, P, et al.
Julkaistu: (2020)

Psoriatic arthritis
Tekijä: FitzGerald, O, et al.
Julkaistu: (2021)

Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis
Tekijä: Victoria Navarro-Compán, et al.
Julkaistu: (2024-05-01)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
Tekijä: Ogdie, A, et al.
Julkaistu: (2023)

Psoriatic arthritis - Tofacitinib as a new treatment
Tekijä: Marta Skorupska, et al.
Julkaistu: (2024-06-01)

Pain reduction in patients with rheumatoid arthritis receiving tofacitinib monotherapy with or without pain medication: A post hoc analysis of pooled data from phase 2, phase 3 and phase 3B/4 studies
Tekijä: Taylor, PC, et al.
Julkaistu: (2019)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
Tekijä: Philip J Mease, et al.
Julkaistu: (2019-06-01)

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
Tekijä: Philip J Mease, et al.
Julkaistu: (2019-06-01)

Itch as the major mediator of the effect of tofacitinib on health-related quality of life in PSA: a mediation analysis
Tekijä: Taylor, P, et al.
Julkaistu: (2020)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
Tekijä: Kevin L. Winthrop, et al.
Julkaistu: (2022-12-01)

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
Tekijä: Lars E. Kristensen, et al.
Julkaistu: (2023-02-01)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
Tekijä: Nash, P, et al.
Julkaistu: (2021)

Post-marketing safety surveillance of tofacitinib over 9 years in patients with psoriatic arthritis and rheumatoid arthritis
Tekijä: Burmester, GR, et al.
Julkaistu: (2023)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
Tekijä: Ly K, et al.
Julkaistu: (2019-08-01)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
Tekijä: Nash, P, et al.
Julkaistu: (2018)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Tekijä: Gerd R. Burmester, et al.
Julkaistu: (2023-07-01)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
Tekijä: Peter Nash, et al.
Julkaistu: (2018-11-01)

Classification and outcome measures for psoriatic arthritis
Tekijä: Leung, Y, et al.
Julkaistu: (2018)